\relax 
\bibstyle{cell}
\select@language{english}
\@writefile{toc}{\select@language{english}}
\@writefile{lof}{\select@language{english}}
\@writefile{lot}{\select@language{english}}
\citation{Fabbri2016}
\citation{Guieze2015}
\citation{Rossi2016}
\citation{Puente2015}
\citation{Landau2015}
\@writefile{toc}{\contentsline {section}{\numberline {1}Introduction}{1}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.1}Aim of the study}{1}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.2}Chronic lymphatic leukemia}{1}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {1.2.1}Common genetic variants}{1}}
\citation{Burns2017}
\citation{Fabbri2016}
\citation{Stevenson2011}
\citation{Cruse2007}
\citation{Fabbri2016}
\citation{Riches2014}
\citation{Aqeilan2009}
\citation{Fabbri2016}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline IGHV status}{2}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline Trisomy12}{2}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline Del13q14}{2}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline TP53 and Del17p13}{2}}
\citation{Fabbri2016}
\citation{Fabbri2016}
\citation{Fabbri2016}
\citation{Li2016}
\citation{Brown2012}
\citation{Jebaraj2013}
\citation{Jebaraj2013}
\citation{Kampjarvi2015}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline Del11q22 and ATM}{3}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline Notch1}{3}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline SF3B1}{3}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline Del8p12 and Gain8q24}{3}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline BRAF}{3}}
\citation{Oakes2016}
\citation{Dietrich}
\citation{Dietrich}
\citation{Wang2009}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline MED12}{4}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline Methylation status}{4}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.3}The primary blood cancer cell encyclopedia}{4}}
\citation{Dobin2015}
\citation{Anders2010}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4}Transcriptome analysis}{5}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {1.4.1}Preprocessing}{5}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {1.4.2}Alignment}{5}}
\citation{Anders2010}
\citation{Love2014}
\citation{Wald1945}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {1.4.3}Exploratory Data Analysis and Quality control}{6}}
\@writefile{toc}{\contentsline {paragraph}{\nonumberline Variance stabilizing transformation}{6}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {1.4.4}Differential gene expression}{6}}
\citation{Subramanian2005}
\citation{Kim2005}
\citation{Fisher1919}
\citation{Fischer2015}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {1.4.5}Enrichment analysis}{7}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {1.4.6}Genetic interaction}{7}}
\citation{Landau2015}
\citation{Ecker2015}
\citation{Ferreira2014}
\citation{Dvinge2014}
\@writefile{lof}{\contentsline {figure}{\numberline {1}{\ignorespaces \textbf  {Genetic interaction on transcriptome level:} Counts (expression) of a certain gene depend on the sample's genotype. In variant A the gene is similar expressed as in wildtype samples, whereas variant B clearly inhibits expression. If both variants co-occur this inhibition is reversed. Variant A either blocks the inhibitory effect of variant B or restores the expression by activation of an alternative pathway. By simple combination of the individual effects we would expect a phenotype similar to the one in variant B, thus both variants interact.\relax }}{8}}
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{fig:geneticInteraction}{{1}{8}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.5}Gene expression in CLL}{8}}
\citation{Dietrich}
\citation{Dietrich}
\citation{Andrews}
\citation{Dobin2015}
\citation{Dobin2015}
\citation{Dobin2015}
\citation{Flicek2014}
\citation{Anders2010}
\citation{Anders2010}
\@writefile{toc}{\contentsline {section}{\numberline {2}Material and Methods}{10}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1}Data}{10}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.1.1}RNA-sequencing}{10}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.2}Data processing}{10}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.1}Raw data}{10}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.2}Alignment}{10}}
\citation{Gu2016}
\citation{RCoreTeam2017}
\citation{RCoreTeam2017}
\citation{Ignatiadis2016}
\citation{Benjamini}
\citation{Love2014}
\citation{Benjamini}
\citation{Varemo}
\citation{Liberzon2015,Kanehisa2017}
\citation{Benjamini}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.3}Statistical analysis}{11}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.2.4}Accounting for T-cell contamination}{11}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.3}Systematic gene Expression Profiling}{11}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.3.1}Differential Expression Analysis}{11}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.3.2}Gene Set Enrichment analysis}{11}}
\citation{Love2014}
\citation{Benjamini}
\citation{Ritchie2015}
\citation{Fischer2015}
\citation{RCoreTeam2017}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.3.3}Multivariate model}{12}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {2.3.4}Tumor epistasis model}{12}}
\citation{Landau2015}
\@writefile{toc}{\contentsline {section}{\numberline {3}Results}{13}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1}Transcriptome data in the Primary blood Cancer Cell encyclopedia (PACE)}{13}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.1}Occurence of genetic variants}{13}}
\@writefile{lof}{\contentsline {figure}{\numberline {2}{\ignorespaces \textbf  {Variants in PACE samples by IGHV status:} Most common genetic variants in CLL samples from the PACE transcriptome data set. The distribution by IGHV status for each variant differs, revealing biases and interactivity between variants.\relax }}{13}}
\newlabel{fig:tableOverview}{{2}{13}}
\@writefile{lof}{\contentsline {figure}{\numberline {3}{\ignorespaces \textbf  {Co-occurrence of genetic variants:} -log10(pvalue) for co-occurrence of genetic variants calculated by $\chi ^2$-square test. The sign indicates the direction of association. Del17p13 and TP53, Del8p12 and Gain8q24, as well as Del11q22.3 and IGHV and Trisomy12 and Del13q14 are significantly associated or excluding.\relax }}{14}}
\newlabel{fig:corplot_Chisquare}{{3}{14}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.2}IGHV status and Trisomy12 form distinct gene expression cluster}{14}}
\citation{Abbasi-Kenarsari2015}
\@writefile{lof}{\contentsline {figure}{\numberline {4}{\ignorespaces \textbf  {Hierarchical clustering of CLL samples based on the 5000 most variable genes:} Unsupervised sample clustering based on the 5000 most variable genes reveals distinct cluster separated by IGHV status, Methylation groups and Trisomy12.\relax }}{15}}
\newlabel{fig:cluster500exprGenes}{{4}{15}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.3}RNA preparation method, IGHV status and Trisomy12 explain major parts of gene expression variance}{15}}
\@writefile{lof}{\contentsline {figure}{\numberline {5}{\ignorespaces \textbf  {Association of genetic variants and principal components:} -log10 (pvalue) t-test for correlation between genetic variants and principal components. PC1 was found to be associated with RNA preparation method and PC2 with IGHV and Del11q22.3. PC3 and PC4 show both significant correlation with Trisomy12 status.\relax }}{17}}
\newlabel{fig:corplot_pca_variants}{{5}{17}}
\newlabel{fig:pca_RNAprep}{{\caption@xref {fig:pca_RNAprep}{ on input line 72}}{18}}
\newlabel{sub@fig:pca_RNAprep}{{}{18}}
\newlabel{fig:pca_IGHV}{{\caption@xref {fig:pca_IGHV}{ on input line 82}}{18}}
\newlabel{sub@fig:pca_IGHV}{{}{18}}
\newlabel{fig:pca_Methylation}{{\caption@xref {fig:pca_Methylation}{ on input line 88}}{18}}
\newlabel{sub@fig:pca_Methylation}{{}{18}}
\newlabel{fig:pca_trisomy12}{{\caption@xref {fig:pca_trisomy12}{ on input line 94}}{18}}
\newlabel{sub@fig:pca_trisomy12}{{}{18}}
\@writefile{lof}{\contentsline {figure}{\numberline {6}{\ignorespaces \textbf  {Principal component analysis by 5000 most variant genes:} \textbf  {(A)} PC1 reflect highest variability within PACE cohort. It correlates with RNA preparation method, which reflects the degree of T-cell contamination. \textbf  {(B)} IGHV status is associated with PC2. \textbf  {(C)} Methylation groups further refine IGHV distinction. \textbf  {(D)} Trisomy12 sample cluster on PC3 and PC4 \relax }}{18}}
\newlabel{fig:pca}{{6}{18}}
\citation{Sturm}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.4}Confounding factors}{19}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.5}Batch effects by adapter contamination}{19}}
\@writefile{lof}{\contentsline {figure}{\numberline {7}{\ignorespaces \textbf  {Number of detected adapter sequences by length of RNAseq reads:} Total numbers and variance of adapter contamination increases drastic with longer reads. This emphasizes the importance of adapter trimming for reads close to the average length of inserts.\relax }}{19}}
\newlabel{fig:adapter_contam}{{7}{19}}
\newlabel{fig:PCA_readlengthOld}{{\caption@xref {fig:PCA_readlengthOld}{ on input line 122}}{20}}
\newlabel{sub@fig:PCA_readlengthOld}{{}{20}}
\newlabel{fig:PCA_readlength_trimmed}{{\caption@xref {fig:PCA_readlength_trimmed}{ on input line 130}}{20}}
\newlabel{sub@fig:PCA_readlength_trimmed}{{}{20}}
\@writefile{lof}{\contentsline {figure}{\numberline {8}{\ignorespaces \textbf  {PCA before and after adapter trimming:} \textbf  {(A)} PCA before adapter trimming: The highest variance is associated with the length of RNAseq reads. \textbf  {(B)} PCA after adapter trimming: Samples can not longer be distinguished by read length.\relax }}{20}}
\newlabel{fig:Trimming}{{8}{20}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.1.6}T-cell contamination}{20}}
\newlabel{fig:TmarkExpression}{{\caption@xref {fig:TmarkExpression}{ on input line 150}}{21}}
\newlabel{sub@fig:TmarkExpression}{{}{21}}
\newlabel{fig:TmarkPCA}{{\caption@xref {fig:TmarkPCA}{ on input line 158}}{21}}
\newlabel{sub@fig:TmarkPCA}{{}{21}}
\@writefile{lof}{\contentsline {figure}{\numberline {9}{\ignorespaces \textbf  {Degree of T cell contamination by marker genes:} \textbf  {(A)} T cell marker gene expression show a gradient between samples, with uniform expression within each sample. \textbf  {(B)} PC1 describes variance by marker gene expression. Thus loadings were used to quantify T cell contamination.\relax }}{21}}
\newlabel{fig:TCell}{{9}{21}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2}Systematic gene Expression Profiling}{22}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.1}IGHV}{22}}
\@writefile{lof}{\contentsline {figure}{\numberline {10}{\ignorespaces \textbf  {Gene expression of differentially expressed genes by IGHV status:} Samples form distinct cluster depending on IGHV status with Trisomy12 samples forming an own cluster. Genes with $>$ 4.5 $\qopname  \relax o{log}_2$ fold change are annotated. Among them are SEPT10, TP63 and TEAD1. Clinical marker ZAP70 and CD38 are up regulated in IGHV unmutated samples.\relax }}{23}}
\newlabel{fig:gene_exprIGHV_gsea_hallmark}{{10}{23}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.2}Trisomy12}{24}}
\@writefile{lof}{\contentsline {figure}{\numberline {11}{\ignorespaces \textbf  {Gene expression in Trisomy12:} Trisomy12 samples form a separate cluster with distinct gene expression. Genes with $\qopname  \relax o{log}_2$ fold changes $>4.5$ are annotated. Among them surface integrins like ITGAM, ITGB2, ITGB1 and ITGB7 can be found. Many up regulated genes are located on chromosome 12.\relax }}{25}}
\newlabel{fig:gene_exprTriisomy12_gsea_hallmark}{{11}{25}}
\newlabel{fig:tri12_chrom_dn}{{\caption@xref {fig:tri12_chrom_dn}{ on input line 206}}{26}}
\newlabel{sub@fig:tri12_chrom_dn}{{}{26}}
\newlabel{fig:tri12_chrom_up}{{\caption@xref {fig:tri12_chrom_up}{ on input line 214}}{26}}
\newlabel{sub@fig:tri12_chrom_up}{{}{26}}
\@writefile{lof}{\contentsline {figure}{\numberline {12}{\ignorespaces \textbf  {Chromosomal distribution of genes differentially expressed in Trisomy12 samples:} \textbf  {(A)} 22\% of up regulated genes are located on chromosome 12. Numbers in captions indicate the number of differentially expressed genes located at this chromosome. \textbf  {(B)} Genes down regulated in Trisomy12 samples are approximately equally distributed among chromosomes.\relax }}{26}}
\newlabel{fig:tri12_chrom}{{12}{26}}
\newlabel{fig:gsea_IGHV}{{\caption@xref {fig:gsea_IGHV}{ on input line 227}}{26}}
\newlabel{sub@fig:gsea_IGHV}{{}{26}}
\newlabel{fig:gsea_trisomy12}{{\caption@xref {fig:gsea_trisomy12}{ on input line 235}}{26}}
\newlabel{sub@fig:gsea_trisomy12}{{}{26}}
\@writefile{lof}{\contentsline {figure}{\numberline {13}{\ignorespaces \textbf  {Enriched hallmark gene sets:} \textbf  {(A)} Enriched pathways in IGHV samples are shown. Up regulated pathway as angiogenesis are higher expressed in IGHV-mutated samples. Down regulated pathways in IGHV mutated vs unmutated samples are TNF alpha signaling via NFKB and PI3 MAP Kinase pathway. \textbf  {(B)} Trisomy12 activates many pathways like TNFA via NFKP, Notch pathway and PI3 MAP Kinase pathway.\relax }}{26}}
\newlabel{fig:EnrichmentTri12IGHV}{{13}{26}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.3}TP53 and Del17p53}{27}}
\@writefile{lof}{\contentsline {figure}{\numberline {14}{\ignorespaces \textbf  {Gene expression in Del17p13 and TP53:} Del17p13 samples cluster together with a few exceptions. Most of these exceptions do not show a TP53 mutation and thus not a complete loss of TP53 function. The cluster is driven by down regulated genes (most located on chromosome 17) including TP53.\relax }}{28}}
\newlabel{fig:gene_exprdel17p13_gsea_kegg}{{14}{28}}
\newlabel{fig:chromosom17_dist_down}{{\caption@xref {fig:chromosom17_dist_down}{ on input line 261}}{29}}
\newlabel{sub@fig:chromosom17_dist_down}{{}{29}}
\newlabel{fig:vennDel17TP53}{{\caption@xref {fig:vennDel17TP53}{ on input line 269}}{29}}
\newlabel{sub@fig:vennDel17TP53}{{}{29}}
\@writefile{lof}{\contentsline {figure}{\numberline {15}{\ignorespaces \textbf  {Distribution of differentially expressed genes in TP53 and Del17p13} \textbf  {(A)} More than half of all down regulated genes in Del17p13 samples are located on chromosome 17. Numbers in captions indicate the number of differentially expressed genes located at this chromosome. \textbf  {(B)} There is a high overlap of differentially expressed genes in TP53 and Del17p13.\relax }}{29}}
\newlabel{fig:GeneDist17}{{15}{29}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.4}Del11q22.3 and ATM}{30}}
\@writefile{lof}{\contentsline {figure}{\numberline {16}{\ignorespaces \textbf  {Gene expression in Del11q22.3 and ATM:} Del11q22 samples cluster driven by deleted genes on chromosome 11 like ATM. Nevertheless loss of ATM function does not seem to be the only driving factor, but a set of genes including SEPT10 is also up regulated.\relax }}{31}}
\newlabel{fig:gene_exprdel11q22.3_gsea_hallmark}{{16}{31}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.5}Del13q14}{32}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.6}Del8p12 and Gain8q24}{32}}
\@writefile{lof}{\contentsline {figure}{\numberline {17}{\ignorespaces \textbf  {Gene expression in Gain8q24 and Del8p12:} Differentially expressed genes in Gain8q24 sample cluster by Gain8q24 and Del8p12 revealing interaction of these variants. Thus, we find up and down regulated genes on chromosome 8 among differentially expressed genes. Genes with $\qopname  \relax o{log}_2$ fold changes $>2$ on chromosome 8 are annnotated.\relax }}{33}}
\newlabel{fig:gene_exprgain8q24_gsea_Hallmark}{{17}{33}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.7}SF3B1}{33}}
\@writefile{lof}{\contentsline {figure}{\numberline {18}{\ignorespaces \textbf  {Gene expression in SF3B1 mutated samples:} Differentially expressed genes in SF3B1 samples form a distinct cluster. SF3B1 mutation is associated with truncated splicing. This leads to coordinated changes on expression level. Genes with $\qopname  \relax o{log}_2$ fold change $>4$ are annotated. \relax }}{34}}
\newlabel{fig:gene_exprSF3B1_gsea_kegg}{{18}{34}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.8}BRAF}{35}}
\@writefile{lof}{\contentsline {figure}{\numberline {19}{\ignorespaces \textbf  {Gene expression in samples with mutated BRAF:} Gene expression in BRAF samples does not show overall coherent cluster. Still a set of up regulated genes that mainly consist of G2M checkpoint genes correlates clearly with BRAF status.\relax }}{36}}
\newlabel{fig:gene_exprBRAF_gsea_Hallmark}{{19}{36}}
\citation{Kampjarvi2015}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.9}MED12}{37}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {3.2.10}Notch1}{37}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3}Multivariate model}{37}}
\@writefile{lof}{\contentsline {figure}{\numberline {20}{\ignorespaces \textbf  {Top 7 genes of significant results in the original model and the multivariate model:} For all variants the numbers of differentially expressed genes were clearly reduced when testing for individual variants in a multivariate model against a reduced model by the likelihood ratio test. The original model included IGHV status, Trisomy12 and degree of T cell contamination as covariate. Still 1012 genes are significantly related to Trisomy12 and 414 related to IGHV status, when we control for the effect of confounding variants. Only a few genes are associated to the other variants.\relax }}{38}}
\newlabel{fig:compModel}{{20}{38}}
\@writefile{lof}{\contentsline {figure}{\numberline {21}{\ignorespaces \textbf  {Most significant differentially expressed genes testing for the effect of each variants alone:} Using a likelihood ratio test to compare a multivariate model with all variants against a reduced model with confounders resulted in small sets of genes related to the individual variants controlling for all other variants. Some of these sets contain less than 7 significant genes. Still we can find known associations like differentially expression of ATM gene in DEL11q22 samples and Notch4 in Notch1 samples.\relax }}{39}}
\newlabel{fig:reducedModel}{{21}{39}}
\citation{Oakes2016}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4}Methylation profiles in gene expression}{40}}
\@writefile{lof}{\contentsline {figure}{\numberline {22}{\ignorespaces \textbf  {Principal component analysis methylation groups:} PC1 and PC2 clearly separate methylation groups into 3 cluster based on expression of the 200 most variable genes.\relax }}{40}}
\newlabel{fig:pca_Meth_top150}{{22}{40}}
\@writefile{lof}{\contentsline {figure}{\numberline {23}{\ignorespaces \textbf  {Gene expression of the 200 most variable genes:} The 200 most variable genes show distinct expression within each methylation group. Among them are multifunctional transcription factors like EGR1, NFAT and EBF1.\relax }}{41}}
\newlabel{fig:gene_expr_Methylationgroups_top150}{{23}{41}}
\citation{Landau2015}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.5}Tumor epistasis in IGHV and Trisomy12}{42}}
\@writefile{lof}{\contentsline {figure}{\numberline {24}{\ignorespaces \textbf  {Genes differentially expressed between samples with Trisomy12, IGHV mutated, both or IGHV-unmutated genotypes:} Genes can be distinguished into 5 groups revealing clear patterns of interactivity. The direction of interaction is consistent within these clusters.\relax }}{43}}
\newlabel{fig:epistasisTri12IGHV}{{24}{43}}
\citation{Ferreira2014}
\citation{Hacken2016}
\citation{Humphries2013}
\citation{Riches2014,Ganghammer2015}
\citation{Strati2017}
\citation{Hacken2016}
\@writefile{toc}{\contentsline {section}{\numberline {4}Discussion}{44}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.1}Gene expression signatures in CLL}{44}}
\@writefile{toc}{\contentsline {subsubsection}{\numberline {4.1.1}B cell receptor signaling is up regulated in IGHV-unmutated samples}{44}}
\citation{Kim2011a}
\citation{Rennoll2015}
\citation{Benedetti2007}
\citation{Landau2015}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.2}Trisomy12 samples show increased expression of integrins driving lymphnode homing}{45}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.3}Down regulation of TP53 is associated with Wnt-signaling}{45}}
\citation{Reyes}
\citation{Knauf2006}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.4}Del11q22 samples cluster by IGHV status}{46}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.5}Interferon signaling and the chaperone UQCC complex are transcriptional regulated in SF3B1 mutated CLLs}{46}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6}Cell cycle progression in G2 phase as a potentially altered pathway in BRAF mutated CLLs}{46}}
\citation{Bulian2017}
\citation{Dietrich}
\citation{Rousseau2016}
\citation{Fatkhutdinov2016}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.7}Genome de-methylation defines subgroups of CLL with distinct gene expression pattern}{47}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.8}Tumor epistasis in Trisomy12 and IGHV results in distinct expression pattern in line with drug response phenotypes}{47}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.9}A multivariate model controls for confounding by other variants and gives insight into gene regulation with another resolution.}{48}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.10}Biases and limitations}{48}}
\citation{Ferreira2014}
\@writefile{toc}{\contentsline {section}{\numberline {5}Conclusion}{50}}
\bibdata{./Biblographie/Thesis}
\@writefile{toc}{\contentsline {section}{\numberline {6}Supplements}{52}}
\@writefile{toc}{\contentsline {subsection}{\numberline {6.1}Gene expression in genetic variants}{52}}
\@writefile{lof}{\contentsline {figure}{\numberline {25}{\ignorespaces \textbf  {Gene expression in Del13q14:} Del13q14 patients do not cluster based on differentially expressed genes. The percentage of deletion or drug response groups does not show any pattern either. We find DLEU1 and some further genes located within the deletion among the differentially expressed genes.\relax }}{52}}
\newlabel{fig:gene_exprdel13q14_gsea_kegg}{{25}{52}}
\@writefile{lof}{\contentsline {figure}{\numberline {26}{\ignorespaces \textbf  {Gene expression in Notch1:} Only 162 genes are differentially expressed in Notch1 mutated samples. Notch1 sample do not cluster by them. Annotations show genes from the Kegg Notch signaling pathway. Only Notch4 is differentially expressed.\relax }}{53}}
\newlabel{fig:gene_exprNOTCH1_gsea_Hallmark}{{26}{53}}
\@writefile{lof}{\contentsline {figure}{\numberline {27}{\ignorespaces \textbf  {Gene expression in MED12:} MED12 mutation has been found in 7 patients. Differential expression analysis reveals significantly different expressed genes in their samples. They do not show distinct pattern, but most MED12 mutated samples cluster by them and MED13L, which is another gene of the mediator complex is among them. Genes with $\qopname  \relax o{log}_2$ fold change $>4$ are annotated.\relax }}{54}}
\newlabel{fig:gene_exprMED12_gsea_Hallmark}{{27}{54}}
\@writefile{toc}{\contentsline {subsection}{\numberline {6.2}Enrichment analysis}{55}}
\newlabel{fig:gseaKegg_IGHV}{{\caption@xref {fig:gseaKegg_IGHV}{ on input line 40}}{55}}
\newlabel{sub@fig:gseaKegg_IGHV}{{}{55}}
\newlabel{fig:gsea_del11q22.3}{{\caption@xref {fig:gsea_del11q22.3}{ on input line 48}}{55}}
\newlabel{sub@fig:gsea_del11q22.3}{{}{55}}
\newlabel{fig:gsea_gain8q24}{{\caption@xref {fig:gsea_gain8q24}{ on input line 54}}{55}}
\newlabel{sub@fig:gsea_gain8q24}{{}{55}}
\newlabel{fig:gsea_SF3B1}{{\caption@xref {fig:gsea_SF3B1}{ on input line 60}}{55}}
\newlabel{sub@fig:gsea_SF3B1}{{}{55}}
\@writefile{lof}{\contentsline {figure}{\numberline {28}{\ignorespaces \textbf  {Enriched gene sets:} \textbf  {(A)} Enriched Kegg pathway in IGHV sample include B cell receptor signaling. It is down regulated in IGHV mutated patients compared to IGHV unmutated patients. \textbf  {(B)} Del11q22 samples are up regulated in Myc targets similar to \textbf  {(C)} Gain8q24 patients \textbf  {(D)} SF3B1 mutation activates many pathways like cholesterol homeostasis, interferon alpha signaling and Notch signaling pathway.\relax }}{55}}
\newlabel{fig:Enrichment_others}{{28}{55}}
